A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Reference |
|---|
| "Severe granulocytopenia is an uncommon complication of infectious mononucleosis, only 18 cases having been reported previously." | ( Boxer, LA; Everett, ED; Landefeld, RA; Stevens, DL, 1979) |
| "Agranulocytosis is a rare side effect of phenytoin treatment." | ( McClune, GL; Sharafuddin, MJ; Spanheimer, RG, 1991) |
| "Drug-induced agranulocytosis is a highly individualized and unexpected reaction to specific drugs." | ( Pisciotta, AV, 1990) |
| "Agranulocytosis is a very rare complication of this autoimmune rheumatic disease as opposed to leucopenia." | ( Alusík, S; Korínková, P; Neuwirtová, R; Pavelka, K; Petrasovicová, V; Trnavský, K, 1990) |
| "Drug-induced agranulocytosis is a clinical entity characterized by a selective reduction of circulating neutrophils, usually to a level less than 0." | ( Escribano, L; Hernández Madrid, A; Odriozola, J; Pérez de Oteyza, J; Pérez Vaquero, MA; Sureda, A, 1990) |
| "Congenital agranulocytosis is a rare fatal infantile disease characterised by recurrent bacterial infections, persistent absence of neutrophils and maturation arrest at the promyelocyte/myelocyte stage." | ( Hassan, HT; Pearson, EC; Rees, JK, 1990) |
| "Thus, the granulocytopenia is not due to 5-azauridine or other catabolic products resulting from deamination." | ( DeSimone, J; Hall, L; Heller, P; Molokie, RE; Zwiers, D, 1985) |
| "Congenital agranulocytosis is a rare and frequently fatal infantile disease characterized by recurrent bacterial infections, persistent absence of neutrophils in the peripheral blood and an arrest of myeloid maturation at the promyelocyte/myelocyte stage." | ( Hassan, HT; Rees, JK, 1989) |
| "Agranulocytosis is a rare but potentially lethal adverse effect of sulfasalazine." | ( Dery, CL; Schwinghammer, TL, 1988) |
| "Agranulocytosis is an infrequent but potentially fatal complication of anti-thyroid drugs." | ( Apthorp, GH; Ostlere, S, 1988) |
| "Among them, agranulocytosis is a severe complication, all the more severe and frequent as it occurs in patients with chronic renal insufficiency, collagen disease, or patient treated with medication having a leucopenic potential." | ( Assyag, P; Brechenmacher, C; Fass, H; Koenig, A, 1987) |
| "A case of severe agranulocytosis is reported in a 43 year old white male with Guillain-Barré syndrome." | ( Brioche, MI; Gouin, F; Martin, C; Ruperti, A; Saux, P, 1985) |
| "A case of agranulocytosis is reported in which amodiaquine, to which the patient had been exposed, was found to be toxic to the patient's bone marrow cells when these were cultured in an agar colony system in vitro." | ( Levi, JA; Lind, DE; Vincent, PC, 1973) |
| "Drug-induced agranulocytosis is relatively rare." | ( Vincent, PC; Young, GA, 1980) |
| "In conclusion, agranulocytosis is the most severe side effect of antithyroid drugs." | ( Benker, G; Lederbogen, S; Meyer-Gessner, M; Olbricht, T; Reinwein, D, 1994) |
| "Since agranulocytosis is considered to be a severe and fatal complication of methimazole therapy, treatment with granulocyte colony stimulating factor seems to be useful for this life-threatening condition." | ( Adorf, D; Grajer, KH; Kaboth, W; Nerl, C, 1994) |
| "Agranulocytosis is the most serious side effect of clozapine therapy, occurring in approximately 1% of all treated patients." | ( Bellnier, TJ; Lamberti, JS; Schneider, E; Schwarzkopf, SB, 1995) |
| "Granulocytopenia is the major dose-limiting factor of this chemotherapy and it takes 4 weeks or more to complete a single course of M-VAC." | ( Hosaka, M; Kondoh, I; Kubota, Y; Miura, T; Noguchi, S; Shuin, T, 1994) |
| "Drug-induced agranulocytosis is a potentially fatal complication despite advances in supportive care." | ( Ng, SC, 1995) |
| "Granulocytopenia is the dose-limiting toxicity." | ( Hohneker, JA, 1994) |
| "Although toxic agranulocytosis is an infrequent disease, its relationship with drugs is well known and its mortality remains high." | ( Aggio, MC; Alvarez, RV; Larregina, A, 1994) |
| "Agranulocytosis is a rare side effect of bucillamine but it is potentially more harmful than other side effects." | ( Hashimoto, M; Hiramatsu, K; Hosaka, M; Iwabuchi, H; Kaga, S; Kanemitsu, H; Kasama, T; Matsuda, A; Negishi, M; Yamazaki, J, 1994) |
| "Although granulocytopenia is relatively common in the later stages of HIV infection, it has only been described once before in the acute stage." | ( King, ME; Skiest, DJ, 1994) |
| "Clozapine-induced agranulocytosis is usually reversible after discontinuation of the drug." | ( Granat, E; Matzner, Y; Oren, R; Shtrussberg, S, 1993) |
| "Agranulocytosis is a rare but sometimes extremely dangerous adverse drug reaction which can be induced by almost any drug." | ( Affolter, H; Meier, C; Schär, B, 1994) |
| "The occurrence of agranulocytosis is a substantial hazard of the administration of clozapine, but this hazard can be reduced by monitoring the white-cell count." | ( Alvir, JM; Lieberman, JA; Safferman, AZ; Schaaf, JA; Schwimmer, JL, 1993) |
| "Agranulocytosis is a well recognized but uncommon complication of procainamide (PA) therapy, whereas a lupus-like syndrome occurs in approximately 20% of patients treated chronically with PA." | ( Creamer, JI; Kenyon, CM; Rubin, RL; Simrell, CR; Starkebaum, G, 1996) |
| "The agranulocytosis is attributed to the use of dipyrone (Dolo-Tiaminol), which the patient obtained in Mexico as a stronger form of generic "aspirin." | ( Cook, J; Dorr, VJ, 1996) |
| "Dapsone-induced agranulocytosis is in common (1/10,000 to 1/20,000)." | ( Callens, A; Gargot, S; Lorette, G; Machet, L; Mercier, E; Vaillant, L, 1996) |
| "Dapsone-induced agranulocytosis is a rare adverse effect." | ( Hiran, S; Pande, TK; Pani, S; Vishwanathan, KA, 1994) |
| "Drug-induced agranulocytosis is a serious adverse effect, occurring at a rate of approximately 6." | ( Pérgola, PE; Sang, JL; Talbert, RL; Whitling, AM, 1997) |
| "Agranulocytosis is one of the most serious side effects to drugs." | ( Alvarez, C; Amutio, E; Cortés, C; Márquez, JA; Pardo, C; Piñán, MA, 1998) |
| "Agranulocytosis is exceptional and occurs late in the disease course." | ( Brazille, P; Coutant-Perronne, V; Malkin, JE; Raguin, G, 2000) |
| "Agranulocytosis is a rare, but serious adverse reaction to sulphasalazine." | ( Rane, A; Stjernberg, E; Wadelius, M; Wiholm, BE, 2000) |
| "Agranulocytosis is a rare, severe and unpredictable idiosyncratic reaction associated with drug therapy that can lead to life-threatening illness." | ( Coleman, MD, 2001) |
| "Drug induced agranulocytosis is a rare condition." | ( Chowdhury, SA; Rahman, J; Wajed, J, 2000) |
| "Agranulocytosis is typically induced by amidopyrine, whereas thrombocytopenia and hemolytic anemia are observed with drugs like quinine-quinidine, betalactams antibiotics, sulfonamides, rifampicin etc." | ( Cheze, S; Leporrier, M, 2001) |
| "Although agranulocytosis is a rare adverse effect of famotidine, the pharmacist and physician should be aware of this potentially fatal event." | ( Bits, H; Clarfield, AM; Da'as, N; Darmon, D; Kleinman, Y; Marcus, EL, 2002) |
| "Agranulocytosis is a potentially lethal adverse drug reaction of dipyrone (metamizole)." | ( Hedenmalm, K; Spigset, O, 2002) |
| "Drug-induced agranulocytosis is an unexpected side effect of a drug, and delay in diagnosis of agranulocytosis can result in a fatal outcome." | ( Imai, T; Itoh, S; Kawada, K; Kusaka, T; Nanba, M; Okada, H, 2003) |
| "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients." | ( Chang, WC; Jin, CJ; Jo, YI; Kim, BK; Shin, SY; Song, JO; Yoon, JH, 2004) |
| "However, agranulocytosis is subject to geographical variability, ratio with at risks ranging from 0." | ( Bentur, Y; Cohen, O, 2004) |
| "Agranulocytosis is a life-threatening disorder that frequently occurs as an adverse reaction to drugs." | ( Andrès, E; Maloisel, F, 2006) |
| "Drug-induced agranulocytosis is a rare but life-threatening side effect which is possibly based on immunogenetic mechanisms." | ( Cascorbi, I; Dettling, M; Krüger, T; Mosyagin, I; Schaub, R, 2005) |
| "Agranulocytosis is a rare and serious disease often caused by drugs." | ( Cavalcanti, AB; Hamerschlak, N, 2005) |
| "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine." | ( Langlois, R; Mancini-Marïe, A; Stip, E; Thuot, C, 2007) |
| "Agranulocytosis is a rare complication of ticlopidine and can be life-threatening." | ( Fun, LC; Karim, F; Rahman, RA; Rajandram, RK; Ramli, R, 2007) |
| "Thionamide induced agranulocytosis is associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCA) in some patients." | ( Finucane, FM; Kinsley, BT; O'Connell, J, 2008) |
| "Agranulocytosis is the most serious complication reported with L1 but, to the best of our knowledge, there are no previous reports on hemorrhagic stroke associated with the use of the agent, and hence, the etiology of the stroke which followed agranulocytosis caused by L1 remains obscure." | ( Inati, A; Koussa, S; Sheikh-Taha, M; Taher, A, 2007) |
| "Dipyrone-related agranulocytosis is an adverse effect more frequent in British population, and its use must be avoided." | ( Faus Felipe, V; García Alegría, J; Mérida Rodrigo, L; Poveda Gómez, F, 2009) |
| "Agranulocytosis is the most serious side effect of deferiprone, with a reported incidence of 0." | ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009) |
| "Drug-induced agranulocytosis is believed to be an extremely rare adverse drug reaction." | ( Chwaluk, P; Siwek-Iwanicka, J, 2009) |
| "Dapsone-induced agranulocytosis is a rare but potentially fatal adverse effect of treatment for tuberculoid leprosy." | ( De Silva, GV; Jayawardana, MA; Murugathas, S; Riyaaz, AA; Satarasinghe, RL; Wickrmasingha, UD; Wijesinghe, R, 2009) |
| "Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal." | ( Ekinci, E; Grossmann, M; Jerums, G; Lee, ST; Yip, G, 2010) |
| "Agranulocytosis/granulocytopenia is a rare side effect of thyreostatics." | ( Eland, IA; Jellema, WT; Stellingwerf, M; Wakelkamp, IM, 2011) |
| "Agranulocytosis is an uncommon but serious complication of Graves' disease under thionamide therapy." | ( Chang, CJ; Chen, YK; Cheng, CY; Lee, TI; Lew, WH; Lin, JD, 2011) |
| "Acquired agranulocytosis is a rare, life-threatening disorder." | ( Afrin, LB, 2012) |
| "Agranulocytosis is a life-threatening disorder characterised by a greatly decreased number of circulating neutrophils below 500/μL." | ( Dybowska, D; Halota, W; Karwowska, K; Kozielewicz, D, 2012) |
| "Agranulocytosis is a rare adverse effect of methimazole." | ( Hong, T; Wen, GB; Xiao, XH; Yang, J; Zhong, J; Zhou, LZ, 2012) |
| "Agranulocytosis is a very serious side-effect of treatment with clozapine." | ( Laan, WJ; Ramlal, D, 2012) |
| "Late-onset agranulocytosis is rare during treatment with clozapine, especially in monotherapy." | ( Cohen, D; Monden, M, 2013) |
| "Agranulocytosis is a rare but dreaded side-effect of thiamazole." | ( Bessembinders, K; Brinkers, JM; de Sonnaville, JJ; van der Linden, PD; van Keulen, K, 2013) |
| "Agranulocytosis is a rare yet life-threatening complication of methimazole therapy for hyperthyroidism." | ( Adedipe, AA; Hosseini, F; Rayner, SG, 2013) |
| "Agranulocytosis is a rare but serious complication of antithyroid drug (ATD) therapy." | ( Imagawa, J; Miyauchi, A; Miyawaki, N; Nakamura, H, 2013) |
| "Agranulocytosis is a serious adverse effect of antithyroid drugs (ATDs) and mainly develops within three months after the start of uninterrupted ATD treatment." | ( Ito, K; Iwaku, K; Kobayashi, S; Kunii, Y; Matsumoto, M; Mukasa, K; Noh, JY; Ohye, H; Sugino, K; Suzuki, M; Watanabe, N; Yoshihara, A, 2014) |
| "Agranulocytosis is a serious complication of antithyroid drugs (ATD) treatment of thyrotoxicosis." | ( Cepková, J; Gabalec, F; Horáček, J; Svilias, I, 2014) |
| "Agranulocytosis is a rare but recognized side-effect to SSZ." | ( Ben Salem, C; Fathallah, N; Hachfi, W; Letaief, A; Rached, S; Slim, R, 2015) |
| "Drug-induced agranulocytosis is a recognized adverse drug event associated with serious infectious complications." | ( Buxton, JA; Carleton, B; Gardy, J; Kuo, M; Omura, J; Purssell, R; Ross, C; Tzemis, D, 2015) |
| "Agranulocytosis is a rare but serious adverse effect of sulfasalazine treatment." | ( Chan, K; Farooq, R, 2015) |
| "Thionamide-induced agranulocytosis is a rare but life-threatening potential side effect of these medicines." | ( Kaysin, A; Viera, AJ, 2015) |
| "Metamizole-related agranulocytosis is rare but potentially life-threatening." | ( Annink-Smoors, M; Hom, HW; Oude Munnik, TH; Sportel, ET, 2016) |
| "Granulocytopenia is the major toxicity associated with cisplatin treatment." | ( Hosoda, H; Kangawa, K; Kimura, T; Miura, K; Miyazato, M; Nojiri, T; Okumura, M; Tokudome, T; Zenitani, M, 2016) |
| "Dapsone-induced agranulocytosis is a rare but potentially fatal adverse drug reaction (ADR)." | ( Božina, N; Čegec, I; Ganoci, L; Juričić Nahal, D; Likić, R; Potočnjak, I; Šimić, I, 2017) |
| "Agranulocytosis is a rare and serious adverse effect of antithyroid drugs, with unknown etiology." | ( Arts, P; Beijers, HJ; Bisschop, PH; de Bruin, IJ; de Herder, WW; Gilissen, C; Hermus, AR; Hoischen, A; Joosten, LA; Knarren, GH; Mulder, AH; Netea, MG; Netea-Maier, RT; Plantinga, TS; Smit, JW; Veltman, JA; Wakelkamp, IM, 2017) |
| "Agranulocytosis is a rare adverse effect of thionamides and elderly patients are especially vulnerable." | ( Bukhari, S; Khan, M; Kumar, N; Mohan, V, 2017) |
| "Agranulocytosis is a serious, although rare, adverse reaction to sulfasalazine, which is used to treat inflammatory joint and bowel disease." | ( Axelsson, T; Bengtsson, M; Bondon-Guitton, E; Carvajal, A; Eriksson, N; Hallberg, P; Ibañez, L; Kohnke, H; Kreutz, R; Lucena, MI; Magnusson, PKE; Martin, J; Molokhia, M; Sancho Ponce, E; Wadelius, M; Yue, QY, 2018) |
| "Agranulocytosis is characterized by a severe decrease or lack of circulating granulocytes." | ( Cosenza, G; Davì, S; Di Franco, F; Fasullo, S; Giubilato, A; La Manna, N; Maringhini, G; Vetrano, G, 2018) |
| "Clinical signs for agranulocytosis are fever, tonsillitis and aphthous stomatitis." | ( Gonnert, FA; Meißner, W, 2018) |
| "Agranulocytosis is an infrequent complication of this antibiotic, postulated in its genesis a mechanism immune-mediated by antineutrophil antibodies and antineutrophil cytoplasm antibodies (ANCA)." | ( Cabrera, MV; Castroagudin, A; di Fonzo, H; Mazzei, ME; Rueda, D; Villegas Gutsch, M, 2018) |
| "Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count." | ( Arora, S; Genchanok, Y; Tolu, SS; Wang, H, 2019) |
| "Agranulocytosis is a rare but potentially fatal complication of this therapy." | ( Antunes, DE; Conceição, SAD; Dias, ML; Jatene, EM; Paula, AF; Paula, SLFM; Rabelo, PN; Reis, MAL; Viggiano, DPPO, 2019) |
| "Thionamide-induced agranulocytosis is a rare complication." | ( Antunes, DE; Conceição, SAD; Dias, ML; Jatene, EM; Paula, AF; Paula, SLFM; Rabelo, PN; Reis, MAL; Viggiano, DPPO, 2019) |
| "Although rare, agranulocytosis is a well-known adverse event of metamizole and led to its withdrawal from the market in a number of countries beginning in the 1960s." | ( Lutz, M, 2019) |
| "Agranulocytosis is a rare but very serious complication of thyrostatic therapy." | ( Barwinek, K; Gąsior-Perczak, D; Kopczyński, J; Kowalska, A; Sitarz-Żelazna, Z; Szczodry, A; Trepka, S, 2020) |
| "Agranulocytosis is the most famous adverse CLZ reaction but is of lesser lethality compared with the other adverse drug reactions of CLZ." | ( Fukuyama, K; Murata, M; Okada, M; Shiroyama, T, 2020) |
| "Agranulocytosis is a rare yet severe idiosyncratic adverse drug reaction to metamizole, an analgesic widely used in countries such as Switzerland and Germany." | ( Amstutz, U; Bonadies, N; Carvajal, A; Cismaru, AL; Eriksson, N; Hallberg, P; Haschke, M; Ibañez, L; Krähenbühl, S; Kreutz, R; Largiadèr, CR; Liakoni, E; Lucena, MI; Martin, J; Molokhia, M; Rudin, D; Sancho Ponce, E; Wadelius, M, 2020) |
| "Agranulocytosis is a rare life-threatening complication of metamizole." | ( Allgaier, R; Gülow, K; Kandulski, A; Maier, L; Müller, M; Tews, HC, 2023) |
| Excerpt | Reference |
|---|
| "Reversible agranulocytosis with life-threatening sepsis occurred in a patient receiving levamisole immunotherapy for colonic carcinoma." | ( Cano, PO; Capek, A; Jerry, LM; Lewis, MG; Mansell, PW; Marquis, G; Parkinson, DR; Shibata, HR, 1977) |
| "Although the incidence of agranulocytosis did not seem to be reduced by any of the treatment schemes, high risk patients could be detected by the single day per week regimen." | ( Mielants, H; Veys, EM, 1978) |
| "Side effects included reversible agranulocytosis in 9 cases, on 3 occasions this necessitated the discontinuation of treatment." | ( Clot, J; Morlock, G; Sany, J; Serre, H, 1977) |
| "A 65-year-old woman developed agranulocytosis on two separate occasions following prophylactic administration of antibiotics before cardiac surgery." | ( Allo, M; Silva, J, 1977) |
| "A third type involves development of agranulocytosis following a latent period during which a sensitive patient is treated with large amounts of chlorpromazine." | ( Pisciotta, V, 1978) |
| "A case of agranulocytosis in a man with nonspecific seronegative polyarthritis treated with levamisole in the form of a proprietary veterinary anthelmintic is described." | ( du P Heyns, A; Retief, FP; Vorster, BJ, 1979) |
| "Two patients with agranulocytosis associated with diphenylhydantoin (DPH) therapy and clinical data suggesting suppression of granulopoiesis were investigated using in vitro culture techniques for committed granulocyte/macrophage precursors." | ( Lane, TA; Mendelsohn, J; Taetle, R, 1979) |
| "Patients with myelotoxic agranulocytosis were treated with gentamicin administered intravenously as drop-wise infusions in a dose of 5 mg/kg body weight a day every 8 hours." | ( Baranov, AE; Bodunkova, LE; Nadezhina, NM; Pozdniakova, VP; Shishkova, TV, 1979) |
| "On the fifth day of cimetidine therapy, agranulocytosis (800/ml) and a very low platelet count (40,000/ml) were observed; bone-marrow failure was documented both by biopsy and aspiration." | ( Druart, F; Frocrain, C; Martin, J; Matuchansky, C; Metois, P, 1979) |
| "In a 75-year-old man, agranulocytosis and septicemia developed after eight weeks of quinidine sulfate therapy." | ( Carr, RM; Eisner, EV; MacKinney, AR, 1977) |
| "She recovered from agranulocytosis after discontinuation of the drug and hospital treatment for 16 days." | ( Brown, BT; Jacknowitz, AI; Prince, RA, 1977) |
| "Thioridazine-hydrochloride-associated agranulocytosis usually occurs between the fifth and 11th week of therapy and is not related to the total dose of drug received." | ( Bogner, PJ; Ferguson, RL; Hodges, GR, 1977) |
| "The frequency of agranulocytosis in association with clozapine therapy has been estimated and compared with data reported for phenothiazine-induced agranulocytosis." | ( Anderman, B; Griffith, RW, 1977) |
| "Thirteen out of 17 deaths from agranulocytosis were attributed to co-trimoxazole treatment." | ( Inman, WH, 1977) |
| "An epidemic of agranulocytosis and granulocytopenia occurred in 1975 in conjunction with clozapine treatment of mental patients in Finland." | ( de la Chapelle, A; Hernberg, S; Kari, C; Nurminen, M, 1977) |
| "A case of agranulocytosis due to dapsone administered for the treatment of acne vulgaris is described." | ( Firkin, FC; Mariani, AF, 1977) |
| "The occurrence of a sudden outbreak of agranulocytosis in Finland among patients being treated with clozapine led to intensive investigations in an attempt to find a local precipitating factor." | ( Amsler, HA; Barth, E; Harjula, K; Teerenhovi, L; Vuopio, P, 1977) |
| "An allergic agranulocytosis developed after promethazine administration to a 34-year-old man with a compulsion neurosis." | ( Engel, H, 1976) |
| "A patient who was diagnosed as having agranulocytosis and thrombocytopenia after treatment with fluconazole was investigated and recovered after withdrawal of the antifungal therapy." | ( Katahira, H; Matsushima, T; Murakami, H; Sakura, T; Sawamura, M; Tamura, J; Tsuchiya, J, 1992) |
| "However, given the risk of agranulocytosis with clozapine, we suggest that the usual treatment strategies for akathisia be tried before clozapine is initiated in the approved manner." | ( Chengappa, KN; Ganguli, R; Kambhampati, RK; Levin, H; Mahdavi, N, 1992) |
| "The relative risk for agranulocytosis during sulphasalazine treatment was calculated to be 107 and 123 by the spontaneous reporting system and the case-control study, respectively." | ( Ekman, E; Keisu, M; Wiholm, BE, 1992) |
| "Granulocytopenia and agranulocytosis are severe side effects of clozapine therapy." | ( Barnas, C; Fleischhacker, WW; Hummer, M; Sperner-Unterweger, B; Stern, A; Zwierzina, H, 1992) |
| "The case of a patient in whom severe agranulocytosis developed after 7 weeks of clozapine treatment is presented." | ( Barnas, C; Fleischhacker, WW; Hummer, M; Sperner-Unterweger, B; Stern, A; Zwierzina, H, 1992) |
| "GM-CSF treatment for severe agranulocytosis deserves further investigation." | ( Jonson, B; Kanerud, L; Palmblad, J, 1990) |
| "Hypoplastic bone marrow associated with agranulocytosis is a well-known side effect of chlorpromazine treatment." | ( Ben-Yehuda, A; Bloom, A; Flusser, D; Lijovetzky, G; Tur-Kaspa, R, 1990) |
| "Two cases of agranulocytosis occurring after addition of a butyrophenone to a course of phenothiazine treatment are reported and possible mechanisms for this interaction are discussed." | ( Kehoe, R; Young, A, 1989) |
| "Four patients (Group I) developed agranulocytosis during a second course of MMI therapy and eight patients (Group II) during an initial course." | ( Komaki, G; Kuma, K; Kumagai, LF; Matsubayashi, S; Morita, T; Nagataki, S; Takaichi, Y; Tamai, H; Walter, RM, 1989) |
| "A 22-year-old female patient developed agranulocytosis 26 days after starting single agent treatment with perazine." | ( Ehninger, G; Gaertner, HJ; Hörner, W, 1985) |
| "Reversible agranulocytosis occurred following approximately 1 week of AZT therapy in a man with AIDS." | ( Goldsmith, JC; Irvine, W, 1989) |
| "Authors describe three cases of agranulocytosis in patients with giant cell (temporal) arterities treated with Dapsone and corticosteroids." | ( Bordessoule, D; Cransac, M; Fourgnaud-Gaillard, S; Liozon, E; Liozon, F; Rousset, H; Vidal, E; Weinbreck, P, 1988) |
| "Seven cases of agranulocytosis and two of liver damage that were probably due to amodiaquine treatment were studied." | ( Fehr, J; Frick, PG; Neftel, KA; Schmid, M; Woodtly, W, 1986) |
| "This paper reports a case of agranulocytosis that developed in a patient with hyperthyroidism two months after the administration of methimazole." | ( Hou, GL; Tsai, CC, 1988) |
| "Aplastic anaemia and agranulocytosis are uncommon but serious adverse effects of drug therapy." | ( Vincent, PC, 1986) |
| "A patient is presented who developed agranulocytosis while taking amodiaquine for suppressive therapy of malaria." | ( Gmür, J; Neftel, K; Schulthess, HK; von Felten, A, 1983) |
| "Because no cases of agranulocytosis were seen with methimazole doses less than 30 mg/d, low-dose methimazole therapy may be safer than high-dose therapy or treatment with conventional doses of propylthiouracil." | ( Cooper, DS; Daniels, GH; Goldminz, D; Ladenson, PW; Levin, AA; Molitch, ME; Ridgway, EC, 1983) |
| "A case of agranulocytosis in an 86-year-old man after 8 weeks treatment with quinidine sulfate is described." | ( Alexander, SJ; Gilmore, RI, 1984) |
| "3 A reversible agranulocytosis has been most commonly observed, occurring between four and six weeks of treatment." | ( Clink, HM, 1983) |
| "A 15-months-old boy developed agranulocytosis after administration of Chloramphenicol and Aminopyrine." | ( Alba, J; Fontán, G; García Rodriguez, MC; Lorente, F; Ojeda, JA, 1980) |
| "While neutropenia and agranulocytosis are not uncommon with chronic chlorpromazine therapy, neutropenia following an acute ingestion is unique but predictable in view of chlorpromazine's toxic effects on white cells." | ( Bruce, W; Burckart, GJ; Snidow, J, 1981) |
| "She developed complete agranulocytosis on peripheral smear within 3 weeks of the initiation of therapy." | ( Balkin, MS; Buchholtz, M; Green, AJ; Ortiz, J, 1993) |
| "Leukopenia and agranulocytosis in combination with a typical bone marrow, exhibiting a complete arrest of myelopoiesis at the stage of promyelocytes led to the diagnosis of an antithyroid therapy induced agranulocytosis." | ( Adorf, D; Grajer, KH; Kaboth, W; Nerl, C, 1994) |
| "Five patients with clozapine-induced agranulocytosis (granulocytes < 500/cu mm) were treated with the rG-CSF filgrastim, in addition to standard agranulocytosis therapy protocol." | ( Gullion, G; Yeh, HS, 1994) |
| "After onset of agranulocytosis, all patients were transferred to a medical service in a university hospital and treated with recombinant granulocyte colony-stimulating factor (filgrastim)." | ( Bellnier, TJ; Lamberti, JS; Schneider, E; Schwarzkopf, SB, 1995) |
| "A case of clozapine-induced agranulocytosis that was treated with a granulocyte colony-stimulating cytokine is presented." | ( Lippmann, SB; Mann, RM; Nguyen, VT; Ryabik, BM; Smith, JD, 1993) |
| "An 82-year-old woman developed agranulocytosis within two months of initiating sulfasalazine therapy." | ( Gales, BJ; Gales, MA, 1993) |
| "Clozapine may produce agranulocytosis in 1-2% of patients treated with it for 4 weeks or longer." | ( Cola, PA; Hasegawa, M; Meltzer, HY, 1994) |
| "The patients with agranulocytosis were treated with antibiotics and the patient with cholestasis received prednisone." | ( Frenkel, J; González, G; Michaud, P; Reyes, C; Téllez, R, 1993) |
| "A case report of clozapine-induced agranulocytosis in a patient treated concomitantly with lithium is reported." | ( Lahav, M; Modai, I; Valevski, A; Weizman, A, 1993) |
| "Episodes of agranulocytosis occurred in 61 patients within three months after they began treatment." | ( Alvir, JM; Lieberman, JA; Safferman, AZ; Schaaf, JA; Schwimmer, JL, 1993) |
| "The occurrence of agranulocytosis is a substantial hazard of the administration of clozapine, but this hazard can be reduced by monitoring the white-cell count." | ( Alvir, JM; Lieberman, JA; Safferman, AZ; Schaaf, JA; Schwimmer, JL, 1993) |
| "Two patients were treated for their agranulocytosis with granulocyte colony-stimulating factor (G-CSF; filgrastim)." | ( Haak, HL; Touw, DJ; van Melick, EJ, 1995) |
| "The average duration of agranulocytosis was not significantly different between the treated and untreated groups (6." | ( Baker, RW; Chengappa, KN; Gopalani, A; Haught, MK; McChesney, K; Schooler, NR, 1996) |
| "We have studied 6 patients with agranulocytosis treated with stimulating factors and 7 patients in historical control group." | ( Góra-Tybor, J; Krykowski, E; Robak, T, 1996) |
| "A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment." | ( Castriota-Scanderbeg, A; Sacco, M, 1997) |
| "For treatment of clozapine-induced agranulocytosis, granulocyte colony-stimulating factors (G-CSF) are recommended." | ( Grond, M; Heiss, WD; Neveling, M; Rudolf, J, 1997) |
| "Reversible agranulocytosis and bone marrow suppression attributed to antibiotics developed in six patients after thiopental administration." | ( Stocker, R; Stover, JF, 1998) |
| "Thirty-nine patients reacted with agranulocytosis, while 75 patients had been treated for a minimum of 3 months without haematological side-effects." | ( Rane, A; Stjernberg, E; Wadelius, M; Wiholm, BE, 2000) |
| "Most of antithyroid drugs-induced agranulocytosis happens 2-12 weeks after the administration of antithyroid drug, and are related with the drug's doses." | ( Dai, W; Jin, H; Xu, B; Zhan, Z; Zhang, J, 1998) |
| "Clozapine medication may induce agranulocytosis in the treatment of a child with a schizophrenic psychosis." | ( Müller, H; Reitzle, K; Warnke, A; Wewetzer, C, 2001) |
| "In 17 of 18 patients, ATD-induced agranulocytosis developed within 2 to 12 weeks of starting ATD treatment." | ( Bai, Y; Dai, WX; Jin, H; Xin, WC; Xu, BZ; Yao, Y; Zhan, SW; Zhang, JD, 2002) |
| "Based on the sudden and late onset of agranulocytosis in our patient, clinicians may consider opting for weekly monitoring of hematologic function for patients on long-term clozapine therapy." | ( Bettinger, TL; Dorson, PG; Patel, NC, 2002) |
| "To calculate the risk of agranulocytosis associated to a drug is required to consider the basal risk of agranulocytosis in a general population as well as its possible modifications in the population of patients treated with the drug." | ( García, AG; Horga de la Parte, JF; Zapater Hernández, P, 2002) |
| "Estimated incidence rates of agranulocytosis in the IAAAS study and the calculated risk of dobesilate-associated agranulocytosis were used as background risks in a Poisson-based methodology, to calculate the number of coincidental reports of agranulocytosis among patients treated with dobesilate." | ( García, A; Horga, JF; Zapater, P, 2003) |
| "We experienced 4 cases of agranulocytosis due to anti-tuberculosis drugs (rifampicin [RFP], isoniazid [INH], ethambutol [EB], streptomycin [SM] or pyrazinamide [PZA]) among some 6,400 tuberculosis patients who underwent chemotherapy over the past 20 years from 1981 to 2002 in our hospital, and the incidence rate of agranulocytosis was estimated at 0." | ( Akagawa, S; Baba, M; Kawabe, Y; Komatsu, H; Kurashima, A; Machida, K; Masuda, K; Nagai, H; Nagayama, N; Shishido, Y; Tamura, A; Yotsumoto, H, 2003) |
| "We report on the first case of agranulocytosis with histological evidence of pure white cell aplasia associated with imipenem-cilastatin treatment." | ( Bourantas, K; Kalambokis, G; Tsianos, EV; Vassou, A, 2005) |
| "This study documents the incidences of agranulocytosis and neutropenia, and the patterns of incidence of the side effects of long-term clozapine treatment in order to determine an appropriate time to stop the Clozaril Patient Monitoring System (CPMS)." | ( Chae, BJ; Cho, MJ; Kang, BJ; Ko, J; Lee, Y; Oh, JT, 2006) |
| "To describe a case of agranulocytosis and severe hepatotoxicity associated with carbimazole treatment." | ( Aguilar-Diosdado, M; de Los Santos, A; Garcia-Valero, A; López-Tinoco, C; Torres, I; Vilchez, FJ, 2006) |
| "We examined the rates of leucopenia and agranulocytosis as reasons for discontinuation of clozapine in a sample of 1875 patients with schizophrenia treated in the State of Maryland." | ( Conley, RR; Dixon, L; Kelly, DL; Kreyenbuhl, J; Love, RC; Medoff, D, 2007) |
| "When neutropenia or agranulocytosis occur in people taking clozapine, cessation of treatment is mandated and relapse often results." | ( Taylor, D; Whiskey, E, 2007) |
| "We report on a patient who presented agranulocytosis and hemolytic anemia associated with this treatment regime." | ( Guedes Filho, G; Guedes, WR; Oliveira, BB; Oliveira, CA; Oliveira, DA; Silva, IM, 2009) |
| "As the risk of a second agranulocytosis is much higher in those patients, various methods of militating against repeat blood dyscrasias have been treated, including granulocyte colony-stimulating factor and lithium." | ( Herceg, M; Jukić, V; Muzinić, L, 2010) |
| "Dapsone-induced agranulocytosis is a rare but potentially fatal adverse effect of treatment for tuberculoid leprosy." | ( De Silva, GV; Jayawardana, MA; Murugathas, S; Riyaaz, AA; Satarasinghe, RL; Wickrmasingha, UD; Wijesinghe, R, 2009) |
| "Non chemotherapy drug-induced agranulocytosis is considered a potentially life-threatening idiosyncratic blood dyscrasia, thought to result from a partly elucidated immune and/or toxic damage on myelopoiesis, due to a multitude of drugs." | ( Papadaki, HA; Pontikoglou, C, 2010) |
| "Two patients experienced agranulocytosis that resolved without complications upon discontinuation of therapy." | ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "In two patients this thiamazole-induced agranulocytosis/granulocytopenia only occurred after years of treatment." | ( Eland, IA; Jellema, WT; Stellingwerf, M; Wakelkamp, IM, 2011) |
| "The pathogenesis of agranulocytosis and pancytopenia might overlap, and additional studies are warranted to clarify this and to establish an optimal treatment strategy." | ( Ito, K; Kami, M; Kobayashi, K; Kunii, Y; Mukasa, K; Narimatsu, H; Noh, JY; Watanabe, N; Yamaguchi, T, 2012) |
| "This article presents two cases of agranulocytosis in patients treated with pegylated interferon and ribavirin due to chronic hepatitis C." | ( Dybowska, D; Halota, W; Karwowska, K; Kozielewicz, D, 2012) |
| "The case was complicated by an agranulocytosis after 3 weeks of antibiotic treatment induced by ceftriaxone." | ( Bertea, M; Braun, D; Günthard, HF; Horovitz, A; Jenni, R, 2010) |
| "This case report describes agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a 70-year-old woman with paroxysmal atrial fibrillation (AF)." | ( Hayashi, H; Horie, M; Kitoh, K; Mitsunami, K, 2012) |
| "The neutropenia reduction to agranulocytosis was followed by successful methotrexate-corticosteroid therapy." | ( Balbir-Gurman, A; Hayek, T; Hoffman, R; Rozin, A, 2013) |
| "This is a rare case of agranulocytosis caused by rifampicin administered during anti-tuberculosis treatment in a chronic renal failure patient." | ( Sugiyama, M, 2012) |
| "Late-onset agranulocytosis is rare during treatment with clozapine, especially in monotherapy." | ( Cohen, D; Monden, M, 2013) |
| "Here, we report a patient who developed agranulocytosis, thrombocytopenia, and severe hepatic dysfunction on day 17 while receiving TZP treatment for an intracranial infection." | ( He, ZF; Wang, YP; Wu, XA, 2013) |
| "Although AMG does not cause agranulocytosis in most animals or humans, drugs associated with serious IDRs generally cause a higher incidence of mild reactions that resolve despite continued treatment." | ( Ng, W; Uetrecht, J, 2013) |
| "However, little is known with regard to agranulocytosis that develops after resumption of the same ATD treatment." | ( Ito, K; Iwaku, K; Kobayashi, S; Kunii, Y; Matsumoto, M; Mukasa, K; Noh, JY; Ohye, H; Sugino, K; Suzuki, M; Watanabe, N; Yoshihara, A, 2014) |
| "There were no cases in which agranulocytosis developed when treatment with the same ATD was resumed after discontinuation for less than five months." | ( Ito, K; Iwaku, K; Kobayashi, S; Kunii, Y; Matsumoto, M; Mukasa, K; Noh, JY; Ohye, H; Sugino, K; Suzuki, M; Watanabe, N; Yoshihara, A, 2014) |
| "In 4 patients, agranulocytosis occurred on MMI treatment, and in 3 patients on CBZ." | ( Cepková, J; Gabalec, F; Horáček, J; Svilias, I, 2014) |
| "We report four cases of agranulocytosis associated with ceftaroline use, highlighted by prolonged use (more than 14 days) and 8-hour dosing intervals or 12-hour dosing intervals with concomitant clindamycin therapy." | ( Chua, J; Lei, LR; Sakoulas, G; Varada, NL, 2015) |
| "In two thirds of the cases, agranulocytosis occurred within 6 weeks of permanent or intermittent metamizole treatment, in 30." | ( Bronder, E; Gundert-Remy, U; Ludwig, WD; Mühlbauer, B; Stammschulte, T, 2015) |
| "To examine the rate of neutropenia and agranulocytosis, and the pattern of development of these 2 disorders among Chinese patients prescribed clozapine treatment in a local psychiatric unit." | ( Lau, KL; Yim, PH, 2015) |
| "There were 114 cases of agranulocytosis attributable to ATD included, and their clinical characteristics and therapy outcomes were analyzed." | ( Dong, MJ; Liu, ZF; Weng, WW; Xu, Q; Yang, J; Zhang, J; Zhong, JJ; Zhu, YJ, 2016) |
| "For patients with ATD-induced agranulocytosis, G-CSF does not improve the recovery time of agranulocytosis, and (131)I is an optimal treatment approach." | ( Dong, MJ; Liu, ZF; Weng, WW; Xu, Q; Yang, J; Zhang, J; Zhong, JJ; Zhu, YJ, 2016) |
| "Clozapine-induced agranulocytosis (CIA)/clozapine-induced granulocytopenia (CIG) (CIAG) is a life-threatening event for schizophrenic subjects treated with clozapine." | ( Fujimoto, M; Fujita, K; Fukao, T; Hashimoto, N; Hashimoto, R; Hashimoto, S; Ikeda, M; Iwata, N; Kamatani, Y; Kanahara, N; Kawase, K; Kida, N; Kimura, T; Kondo, K; Kubo, M; Kubota, M; Makinodan, M; Murakami, M; Mushiroda, T; Nemoto, K; Nishihata, Y; Noda, T; Numata, S; Ohi, K; Ohmori, T; Otsuru, T; Ozeki, T; Saito, T; Shimasaki, A; Suwa, T; Takahashi, A; Takaki, M; Takeda, M; Ueno, S; Yada, Y; Yamamori, H; Yasuda, Y, 2016) |
| "Blood dyscrasias excluding agranulocytosis received limited attention in antipsychotic-treated patients during the first 18 weeks of therapy, although severe clinical conditions have been reported in a few cases." | ( Catapano, F; Fabrazzo, M; Maj, M; Monteleone, AM; Perris, F; Prisco, V; Sampogna, G, 2017) |
| "This case report describes agranulocytosis immediately after oral administration of dabigatran in a 68 years old man with atrial fibrillation (AF)." | ( Cosenza, G; Davì, S; Di Franco, F; Fasullo, S; Giubilato, A; La Manna, N; Maringhini, G; Vetrano, G, 2018) |
| "CONCLUSIONS Agranulocytosis induced by vancomycin is infrequent and generally occurs after day 12 of treatment." | ( Cabrera, MV; Castroagudin, A; di Fonzo, H; Mazzei, ME; Rueda, D; Villegas Gutsch, M, 2018) |
| "A 37-year-old Japanese female developed agranulocytosis and severe alopecia after initiation of AZA (50 mg), used as an alternative to mycophenolate mofetil (MMF, 1000 mg) therapy in anticipation of a planned pregnancy." | ( Andoh, A; Ishikura, K; Kamei, K; Kano, Y; Matsumura, S; Ogura, M; Saida, K; Sato, M, 2018) |
| "Prevalence estimates of agranulocytosis and related death in clozapine-treated patients were synthesized with the Comprehensive Meta-Analysis program using the random-effects model." | ( Li, XH; Lu, L; Ng, CH; Rao, WW; Ungvari, GS; Wang, G; Wang, S; Wang, SB; Xiang, YT; Zheng, W; Zhong, XM, 2020) |
| "We report a case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy." | ( Arora, S; Genchanok, Y; Tolu, SS; Wang, H, 2019) |
| "Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count." | ( Arora, S; Genchanok, Y; Tolu, SS; Wang, H, 2019) |
| "The inherent risk of agranulocytosis associated with clozapine requires the realization of weekly white blood cell monitoring (WBCM) during the 18 first weeks of treatment." | ( Artarit, P; Chaslerie, A; Grall-Bronnec, M; Guerlais, M; Istvan, M; Jolliet, P; Laforgue, EJ; Vallot, G; Victorri-Vigneau, C, 2021) |
| "However, the high risk of agranulocytosis associated with clozapine therapy limits its clinical application." | ( Matsumoto, A; Noda, Y; Ozaki, N; Tashiro, Y; Torii-Goto, A; Ukigai, M; Yoshimi, A, 2022) |